Trial reportJournal of pain research2025
Effective Dosage of Ciprofol for the Induction of General Anesthesia Across Diverse Age Groups in Adults: A Single-Center, Prospective, Non-Randomized Sequential Trial.
Trial report in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Optimal dosing of ciprofol for gastrointestinal endoscopy: a systematic review and network meta-analysis.BMC gastroenterology · 2025Pooled it
- Age-related reduction in ciprofol requirement for loss of consciousness during anesthesia induction: a prospective cohort study.Frontiers in medicine · 2026Trial
- Median effective dose (ED50) of ciprofol combined with alfentanil for suppressing cervical dilation responses during hysteroscopy: a prospective Dixon up-and-down study.BMC anesthesiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: A new Chinese-developed intravenous anesthetic called ciprofol enhances propofol's effectiveness against GABAA receptors by adding cyclopropyl. This study aims to determine the optimal dosage of ciprofol for inducing general anesthesia in adult patients of different ages and its correlation with Narcotrend index (NTI). Patients and Methods: 105 patients were stratified into three age groups: 18-40 (Group A), 41-65 (Group B), and 66-85 (Group C) years. Initial doses of 0.4 mg/kg (Groups A and B) and 0.3 mg/kg (Group C) ciprofol tosilate were administered, adjusted by 0.05 mg/kg based on sedation efficacy. The Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale and Dixon up-and-down method were used to calculate ED50, ED95, and NTI50. Results: Effective dosages were: youth (ED50=0.526 mg/kg, ED95=0.610 mg/kg), middle-aged (ED50=0.366 mg/kg, ED95=0.450 mg/kg), and elderly (ED50=0.324 mg/kg, ED95=0.408 mg/kg). NTI50 were 38.068 (33.496-44.188), 44.963 (39.311-52.270), and 47.214 (39.792-57.420) for the three groups, respectively. Conclusion: Ciprofol is safe and effective for anesthesia induction across age groups, with lower doses required for elderly patients. NTI reduction was dose-dependent and slower in elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.